There are> 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of
action currently approved by the US Food and Drug Administration for the treatment of …

This review addresses current changes in the approach to treating patients with multiple
sclerosis (MS). The widely practiced approach of utilizing agents with lower treatment …

Monoclonal antibodies have become a mainstay in the treatment of patients with relapsing
multiple sclerosis (RMS) and provide some benefit to patients with primary progressive MS …

Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica
spectrum disorder (NMOSD) has evolved very rapidly and a large number of disease …

Multiple sclerosis is an important neurological disease affecting millions of young patients
globally. It is encouraging that more than ten disease-modifying drugs became available for …

Multiple sclerosis (MS) is a chronic autoimmune demyelinating and neurodegenerative
disease of the central nervous system with a wide variety of clinical phenotypes. In spite of …

Background and objectives: Alemtuzumab demonstrated superior efficacy versus
subcutaneous interferon (IFN) beta-1a in participants with relapsing-remitting multiple …

Development of disease-modifying therapies including monoclonal antibody (mAb)-based
therapeutics for the treatment of multiple sclerosis (MS) has been extremely successful over …

Cladribine tablets (CladT) is a highly active oral disease-modifying therapy (DMT) for the
management of relapsing multiple sclerosis (RMS). CladT acts as an immune reconstitution …

Background: Alemtuzumab efficacy and safety was demonstrated in CARE-MS I and
extension studies (CAMMS03409; TOPAZ). Objective: Evaluate serum neurofilament light …